To empower people with a simple breath test that provides early detection of cancer and other diseases.
A non-invasive screening test to save lives.
Our quality statement
Our commitment to quality saves lives.
Our quality policy
Picomole is committed to developing, manufacturing and supporting high-quality products and services that provide unique benefits to our customers. We will always focus our efforts on delivering innovative solutions to our customers' needs.
In addition to the value and quality inherent in our product offerings, we strive to provide service and support that continually exceeds our customers' expectations.
We regularly seek the input of our customers in assessing our success, and measure quality through the degree of usefulness and satisfaction experienced by our customers.
Customer feedback and internal reviews are the basis for ensuring our system complies with all internal and external quality requirements and provides an avenue for continuous improvement.
Who we are
In 2005, Picomole was founded in Edmonton, Alberta, as a spin out from the University of Alberta. In 2008, Picomole completed its first gas analyzer prototype. Picomole relocated to Moncton, New Brunswick in 2011, where the first breath sampler prototype was created that same year. After nationally incorporating in 2013, Picomole ceased operations until 2016, when Picomole refinanced. In 2018, Picomole took a large step in becoming the company that it is today by hiring Dr. Stephen Graham as CEO. Under the guidance of Dr. Graham in 2018, Picomole completed a preliminary study for a lung cancer screening model. Picomole has now completed a proof of concept (POC) study for lung cancer, and is in the process of completing the breast cancer POC. Picomole is poised to change the way disease is detected for years to come.